Targeted Protein Degraders for Neurologic Disease

Abstract

Targeted protein degraders (TPDs), including proteolysis targeting chimeras (PROTACs) and molecular glues, represent a novel therapeutic paradigm with significant potential for the management of neurologic diseases. By harnessing the ubiquitin-proteasome system to selectively degrade pathogenic proteins, these agents address limitations of conventional inhibitors, offering new hope for neurodegenerative and rare neurologic conditions. This review synthesizes current evidence, elucidates mechanisms of action, and discusses clinical implications, recent advances, and future directions for TPDs in neurology, with emphasis on their translational relevance for clinicians.

Introduction

Neurologic diseases such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), Huntington's disease, and various ataxias are characterized by aberrant protein accumulation and misfolding, leading to progressive neuronal dysfunction and degeneration. Despite advances in symptomatic management, disease-modifying therapies remain limited. Targeted protein degradation represents a disruptive strategy, providing an opportunity to eliminate rather than inhibit aberrant proteins and thereby modify disease trajectories. This article reviews the landscape of TPDs in neurologic disease, integrating mechanistic insights, epidemiological relevance, clinical characteristics, and guideline considerations for practicing clinicians.

Epidemiology / Disease Burden

Neurodegenerative disorders collectively impose a significant global burden, with Alzheimer's disease (AD) affecting over 50 million individuals worldwide, and Parkinson's disease (PD) prevalence exceeding 10 million. ALS and Huntington's disease, though rarer, markedly impact quality of life and healthcare resources. The progressive and incurable nature of these conditions underscores the urgent need for disease-modifying interventions. Current estimates suggest the prevalence of proteinopathies will increase with aging populations, further amplifying the necessity for novel mechanistic therapies such as TPDs.

Pathophysiology

Many neurologic diseases are characterized by the accumulation of misfolded or aggregation-prone proteins, which disrupt neuronal homeostasis. In AD, tau and amyloid-β aggregates are central; in PD, α-synuclein forms Lewy bodies. Similarly, mutant huntingtin in Huntington's disease and TDP-43 or SOD1 in ALS drive pathology. Traditional therapies often fail to address these aggregative processes directly. TPDs utilize bifunctional small molecules that bridge target proteins to E3 ubiquitin ligases, tagging them for proteasomal degradation. This approach enables the elimination of pathogenic proteins, even those considered 'undruggable' by classical inhibition.

Risk Factors

Genetic predisposition plays a pivotal role in many neurologic proteinopathies, such as familial forms of AD, PD, and ALS. Environmental exposures, aging, and comorbidities also modulate risk by influencing protein misfolding, clearance, and neuronal vulnerability. Understanding these risk factors aids in identifying patient populations that may benefit from early intervention using TPDs, especially in genetically defined cases where pathogenic protein overexpression is evident.

Clinical Features

Clinical manifestations of neurodegenerative diseases are diverse, reflecting the affected neuronal circuits. AD presents with progressive cognitive decline, memory impairment, and executive dysfunction. PD is marked by bradykinesia, tremor, rigidity, and later cognitive impairment. ALS features progressive muscle weakness and atrophy, while Huntington's disease presents with chorea, psychiatric symptoms, and cognitive dysfunction. Symptom progression correlates poorly with existing therapies, highlighting the need for approaches that alter pathogenic protein load, as TPDs may offer.

Diagnosis

Diagnosis typically relies on clinical assessment, supported by neuroimaging, cerebrospinal fluid biomarkers, and genetic testing. However, biomarkers for direct monitoring of protein aggregation, clearance, or degradation are emerging. The development of reliable assays for target engagement and protein degradation in vivo will be critical for assessing TPD efficacy in clinical trials and practice.

Treatment & Management

Current therapeutic approaches for neurodegenerative diseases are predominantly symptomatic, targeting neurotransmitter deficits or providing supportive care. Cholinesterase inhibitors, levodopa, riluzole, and tetrabenazine are mainstays, but do not address underlying proteinopathies. Disease-modifying strategies, including monoclonal antibodies and antisense oligonucleotides, have shown limited or variable success. TPDs offer a fundamentally different approach by reducing levels of disease-driving proteins, with the potential for greater and more sustained disease modification.

Recent Advances / Emerging Therapies

Recent years have witnessed significant progress in the development of brain-penetrant TPDs. PROTACs targeting tau, α-synuclein, and mutant huntingtin have demonstrated preclinical efficacy, reducing aggregate load and ameliorating behavioral deficits in animal models. Molecular glues and other TPD scaffolds targeting previously intractable proteins are under investigation. Key challenges include optimizing blood-brain barrier penetration, minimizing off-target effects, and ensuring selective degradation. Early-phase clinical trials are underway, with promising pharmacokinetics and pharmacodynamics reported for several candidates. Notably, advancements in E3 ligase ligand discovery and linker chemistry are accelerating the field toward clinical translation.

Guideline Recommendations

While no targeted protein degraders have yet achieved regulatory approval for neurologic diseases, expert consensus and evolving guidelines recognize their potential. The American Academy of Neurology and related bodies encourage enrollment in clinical trials evaluating disease-modifying therapies, including TPDs, for eligible patients. Ongoing trials emphasize the importance of biomarker-driven patient selection and longitudinal monitoring of both safety and target engagement. As data mature, guidelines will likely evolve to incorporate TPDs alongside or in place of traditional disease-modifying agents for select indications.

Conclusion

Targeted protein degraders represent a transformative approach for neurologic diseases, offering the possibility of directly eliminating pathogenic proteins implicated in disease progression. As preclinical and early clinical data continue to accrue, these agents may redefine the therapeutic landscape for disorders such as Alzheimer\"s, Parkinson\"s, ALS, and Huntington\"s disease. Ongoing research addressing delivery, selectivity, and safety will be critical for successful clinical translation. For clinicians, understanding the mechanism and clinical promise of TPDs will be essential as they move closer to routine practice, heralding a new era in the management of neurodegenerative disease.